Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 2, 2002, Pages 540-548

  Osborn, Blaire L ^a   Olsen, Henrik S ^a   Nardelli, Bernardetta ^a   Murray, James H ^a   Zhou, Joe X H ^a   Garcia, Andrew ^a   Moody, Gordon ^a   Zaritskaya, Liubov S ^a   Sung, Cynthia ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALBUMIN ALPHA INTERFERON; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; MESSENGER RNA; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HEPATITIS B; HEPATITIS C; MALE; MELANOMA; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BURKITT LYMPHOMA; CELL DIVISION; CELL LINE; COS CELLS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MACACA FASCICULARIS; MALE; RNA, MESSENGER; SERUM ALBUMIN;

EID: 0036827834     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037002     Document Type: Article

References (35)

1. Ahmed A and Keeffe EB (1999) Overview of interferon therapy for chronic hepatitis C. Clin Liver Dis 3:757-773.
2. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, et al. (2001) Rational design of a potent, long-lasting form of Interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α2a for the treatment of hepatitis C. Bioconjug Chem 12:195-202.
3. Chinery SA and Hinchliffe E (1989) A novel class of vector for yeast transformation. Curr Genet 1:21-25.
4. Collins JM, Riccardi R, Trown P, O'Neill D, and Poplack DG (1985) Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: Comparison of intravenous, intramuscular and intraventricular delivery. Cancer Drug Deliv 2:247-253.
5. Damen M, Weegink CJ, Mauser-Bunschoten EP, Cuypers HT, Hermus MC, Sillekens P, Haan E, van den Berg HM, Bresters D, Lelie PN, et al. (2001) Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: A multicenter, randomized, controlled study. Scand J Gastroenterol 36:97-104.
6. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al. (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 321:1501-1506.
7. Fischer T, Aman J, van der Kuip H, Rudolf G, Peschel C, Aulitzky WE, and Huber C (1996) Induction of interferon regulatory factors, 2′-5′ oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness. Br J Haematol 92:595-603.
8. Drugs and Therapeutics [Medical Letter] (1997) Drugs for non-HIV viral infections. Med Lett Drugs Ther 39 (1006):69-76.
9. Food and Drug Administration (2000) Toxicologist's Review, BLA 99-1488.
10. Foster GR (1997) Interferons in host defense. Semin Liver Dis 17:287-295.
11. Fried MW and Hoofnagle JH (1995) Therapy of hepatitis C. Semin Liver Dis 15:82-91.
12. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, and the Hepatitis C Intervention Therapy Group (2000) Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther 68:556-567.
13. Hinchliffe E and Chinery SA (1994) inventors, Delta Biotechnology Limited, assignee. European patent 0286424. 1994, March 16.
14. Hinchliffe E and Chinery SA (1997) inventors, Delta Biotechnology Limited, assignee. US patent 5,637,504, 1997, June 10.
15. Hu KQ, Vierling JM, and Redeker AG (2001) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepatitis 8:1-18.
16. Kramer MJ, Dennin R, Kramer C, Jones G, Connell E, Rolon N, Gruarin A, Kale R, and Trown PW (1983) Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res 3:425-435.
17. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chincilla D, Roschke V, et al. (2001) Interferon-κ, a novel type I IFN expressed in human keratinocytes. J Biol Chem 276:39765-39772.
18. Maeyer E and Maeyer-Guignard J (1998) Interferons, in The Cytokine Handbook, 3rd Ed (Thompson A ed) pp 491-516, Academic Press, San Diego.
19. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, and Green JD (1991) Interspecies scaling of clearance and volume of distribution for five therapeutic proteins. Pharm Res (NY) 8:1351-1359.
20. Moritz T, Weissmann B, Grunewald B, Hust H, Kummer G, and Niederle N (1992) Induction of 2′-5′ oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia. Mol Biother 4:97-102.
21. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, and Hooftman L (2001) Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 19:1312-1319.
22. Murashima S, Kumashiro R, Ide T, Miyajima I, Hino T, Koga Y, Ishii K, Ueno T, Sakisaka S, and Sata M (2000) Effect of interferon treatment on serum 2′,5′-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol 62:185-190.
23. Naik DN and Khattree R (1999) Applied Multivariate Statistics with SAS Software, 2nd Ed. John Wiley and Sons, New York.
24. Perry CM and Jarvis B (2001) Peginterferon-alpha-2a (40kD): A review of its use in the management of chronic hepatitis C. Drugs 61:2263-2288.
25. Peters T (1996) All About Albumin. Academic Press, San Diego.
26. th anniversary of the discovery of interferons. Cancer Res 58:2489-2499.
27. Rubinstein S, Familletti PC, and Pestka S (1981) Convenient assay for interferon. J Virol 37:P755-758.
28. Runkel L, Pfeffer L, Lewerenz M, Monneron D, Yang CH, Murti A, Pellegrini S, Goelz S, Uzé G, and Mogensen K (1998) Differences in activity between α and β type I Interferons explored by mutational analysis. J Biol Chem 273:8003-8008.
29. Syed S, Schuyler PD, Kulczycky M, and Sheffield WP (1997) Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 89:3243-3252.
30. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, and Kantarjian HM (2001) Phase I study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 98:1708-1713.
31. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, and Poynard T (2001) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. J Viral Hepatitis 8:48-62.
32. Tine F, Magrin S, Craxi A, and Pagliaro L (1991) Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 13:192-199.
33. Trown PW, Wills RJ, and Kamm JJ (1986) The preclinical development of Roferon®-A. Cancer 57:648-1656.
34. Wills RJ, Spiegel HE, and Soike KF (1984) Pharmacokinetics of recombinant alpha A interferon following intravenous infusion and bolus, IM and PO administrations to African green monkeys. J Interferon Res 4:399-409.
35. Yeh P, Landais D, Lemaitre M, Maury I, Crenne JY, Becquart J, Murry-Brelier A, Boucher F, Montay G, Fleer R, et al. (1992) Design of yeast-secreted albumin derivatives for human therapy: Biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA 89:1904-1908.